5-tert-butyl-2-hydroxymethylfuran | 63711-16-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 5-tert-butyl-2-hydroxymethylfuran
• 英文别名: (5-tert-butyl-furan-2-yl)-methanol；5-tert.-Butyl-furfuryl-alkohol；5-t-Butylfurfurylalkohol；(5-Tert-butylfuran-2-yl)methanol
• CAS: 63711-16-0
• 化学式: C₉H₁₄O₂
• 分子量: 154.209
• InChiKey: SWNULDSPUKOPJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  33.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-tert-butyl-2-hydroxymethylfuran 在 吡啶 、 氯化亚砜 作用下， 以 Petroleum ether 为溶剂， 反应 3.0h， 以2.3 g的产率得到5-t.Butylfurfurylchlorid
  参考文献：
  名称：

  Synthesis and Phosphorylation of 2-, 3-, and 4-Halomethyl-5-tert-butylfurans

  摘要：

  Synthetic methods for preparing of 2-, 3-, and 4-halomethyl-5-tert-butylfurans are developed. It was established that the bromination of 3- and 4-methyl-2-tert-butylfurans with N-bromosuccinimide proceeds mainly at the free alpha-position of the furan ring, and not at the methyl group. Therefore, the target halomethylfurans were prepared through the corresponding 3- and 4-methoxymethyl derivatives. The obtained five products were phosphorylated with sodium diethyl phosphite under the conditions of the Michaelis-Becker reaction to give the corresponding phosphonates.

  DOI：

  10.1023/b:rugc.0000031868.97123.e1
• 作为产物：
  描述：

  5-叔丁基呋喃-2-羧酸甲酯 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 以3.6 g的产率得到5-tert-butyl-2-hydroxymethylfuran
  参考文献：
  名称：

  Synthesis and Phosphorylation of 2-, 3-, and 4-Halomethyl-5-tert-butylfurans

  摘要：

  Synthetic methods for preparing of 2-, 3-, and 4-halomethyl-5-tert-butylfurans are developed. It was established that the bromination of 3- and 4-methyl-2-tert-butylfurans with N-bromosuccinimide proceeds mainly at the free alpha-position of the furan ring, and not at the methyl group. Therefore, the target halomethylfurans were prepared through the corresponding 3- and 4-methoxymethyl derivatives. The obtained five products were phosphorylated with sodium diethyl phosphite under the conditions of the Michaelis-Becker reaction to give the corresponding phosphonates.

  DOI：

  10.1023/b:rugc.0000031868.97123.e1

文献信息

• HETEROCYCLIC INHIBITORS OF MCT4
  申请人：Vettore, LLC

  公开号：US20180162822A1

  公开（公告）日：2018-06-14

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一些化合物和组合物，适用于治疗由MCT4介导的疾病，如增殖性和炎症性疾病，其结构如下所示： 还提供了在人类或动物主体中抑制MCT4活性的方法。
• NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION
  申请人：SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.

  公开号：US20200190091A1

  公开（公告）日：2020-06-18

  A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. (I)

  一种含氮杂环化合物，一种制备方法，一种中间体，一种组合物和一种应用。本发明提供一种由式I表示的含氮杂环化合物，其药学上可接受的盐，其对映体，其非对映异构体，其互变异构体，其溶剂合物，其代谢物或其前药。该化合物对ErbB2酪氨酸激酶具有高抑制活性，对表达ErbB2高的人类乳腺癌细胞BT-474，人类胃癌细胞NCI-N87等具有良好的抑制活性，并且对EGFR激酶具有相对较弱的抑制活性，即该化合物是一种减弱EGFR激酶抑制活性的EGFR/ErbB2双靶点抑制剂或具有选择性作用于ErbB2靶点的小分子抑制剂。 (I)
• HETEROCYCLIC CETP INHIBITORS
  申请人：Salvati E. Mark

  公开号：US20070161685A1

  公开（公告）日：2007-07-12

  Compounds of formula Ia and Ib wherein A, B, C and R 1 are described herein.

  式Ia和Ib的化合物 其中A、B、C和R1 如本文所述。
• PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVIC

  公开号：US20160039872A1

  公开（公告）日：2016-02-11

  The invention provides novel compounds that may serve as anticancer therapeutics. The compounds of the invention bind to polo-like kinases through the polo-box domain. In certain embodiments, the compounds of the invention are POM-protected peptide derivatives. The use of cationic bis-alkyl his residues in combination with a mono POM-protected pho-phoryl group results in a peptide possessing an overall neutral charge. The peptide derivatives of the invention have achieved both good efficacy and an enhanced bioavailability. The invention also provides methods of use, compositions, and kits thereof. Further, the invention provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.

  该发明提供了可能用作抗癌治疗的新化合物。该发明的化合物通过波洛盒结构结合到波洛样激酶。在某些实施方式中，该发明的化合物是POM保护的肽衍生物。在结合了阳离子双烷基组氨酸残基和单个POM保护的磷酸化基团的情况下，得到的肽具有整体中性电荷。该发明的肽衍生物既具有良好的疗效又具有增强的生物利用度。该发明还提供了使用方法、组合物和相关试剂盒。此外，该发明提供了一种新的设计和/或合成磷酸化肽衍生物的方法，这些衍生物可用作治疗剂。
• PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE
  申请人：Burke, JR. Terrence R.

  公开号：US20120065146A1

  公开（公告）日：2012-03-15

  Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment of hyperproliferative disorders, particularly cancer. Also provided are uses of the compounds for the preparation of a medicament.

  在各种真核生物中发现的波罗样激酶（Plks）是一类保守的Ser / Thr蛋白激酶亚家族，它们在细胞增殖中发挥关键作用。本文提供了特异性抑制Plks，特别是Plk1活性的化合物。本文还提供了使用这些化合物治疗高增殖性疾病，特别是癌症的方法。此外，还提供了使用这些化合物制备药物的用途。